Catalog No.
Product Name
Application
Product Information
Citations
-
HDAC Inhibitor
HDAC-IN-31 is a selective and orally active histone deacetylase (HDAC) inhibitor, exhibiting IC50 values of 84.90 nM for HDAC1, 168.0 nM for HDAC2, 442.7 nM for HDAC3, and greater than 10,000 nM for HDAC8. This compound induces apoptosis and triggers G2/M phase cell cycle arrest, demonstrating significant antitumor efficacy. HDAC-IN-31 is applicable in research focused on diffuse large B-cell lymphoma and other cancer studies. -
Topoisomerase/HDAC Inhibitor
Top/HDAC-IN-1 is a dual inhibitor targeting both topoisomerase and histone deacetylases (HDACs), demonstrating IC50 values of 18 nM for HDAC1, 230 nM for HDAC2, 790 nM for HDAC3, 87 nM for HDAC6, and 5250 nM for HDAC8. This compound exhibits significant antitumor activity against HCT116 cells, with an IC50 of 180 nM, effectively inducing apoptosis and promoting G2 cell cycle arrest. Top/HDAC-IN-1 serves as a valuable tool in cancer research, particularly for studies involving epigenetic modulation and cell proliferation. -
mTOR/HDAC6 Inhibitor
mTOR/HDAC6-IN-1 is a potent dual inhibitor targeting mTOR and HDAC6, exhibiting IC50 values of 133.7 nM and 56 nM, respectively. This compound is known to induce significant autophagy and apoptosis while suppressing cell migration. It holds potential for research applications in triple-negative breast cancer (TNBC) studies, offering insights into the interplay between these critical pathways in cancer progression. -
HDAC Inhibitor
HDAC-IN-59 is a potent inhibitor of histone deacetylases (HDACs), demonstrating significant biological activity in cancer research. This compound promotes the generation of reactive oxygen species (ROS), leading to DNA damage and the induction of apoptosis via the mitochondria-related pathway. Additionally, HDAC-IN-59 effectively disrupts the cell cycle at the G2/M phase, making it a valuable tool for studying the mechanisms of cell growth regulation and apoptosis in various cancer models. -
Antitumor Agent
SpiD3, a spirocyclic dimer, functions as an antitumor agent with significant inhibitory effects on malignant B-cell proliferation. It suppresses NF-κB activation independently of tumor microenvironment-related stimuli, promoting apoptosis and inhibiting protein synthesis in chronic lymphocytic leukemia (CLL) cells. SpiD3 is suitable for research focused on the mechanisms of CLL and the development of targeted therapies. -
S100P Inhibitor
5-Methyl cromolyn disodium is a selective inhibitor of the S100P protein, targeting its interaction with the receptor for advanced glycation end-products (RAGE). It effectively suppresses NF-κB activity and cell proliferation while enhancing Gemcitabine-induced apoptosis. In preclinical mouse models, 5-Methyl cromolyn disodium demonstrates significant anti-tumor effects by reducing growth and metastasis of pancreatic ductal adenocarcinoma (PDAC), ultimately extending survival. This compound serves as a valuable tool for investigating pancreatic cancer mechanisms and potential therapeutic approaches. -
JAK/HDAC Inhibitor
JAK/HDAC-IN-2 is a dual-target inhibitor of Janus kinase (JAK) and histone deacetylase (HDAC), specifically inhibiting HDAC3/6 and JAK1/2 with nanomolar potency. This compound demonstrates proapoptotic activity by inhibiting histone deacetylation and STAT3 phosphorylation, contributing to its mechanism of action. JAK/HDAC-IN-2 exhibits significant antiproliferative effects in various hematological malignancies and solid tumors, making it a valuable tool for cancer research and therapeutic studies. -
c-Met/HDAC Inhibitor
c-Met/HDAC-IN-2 is a highly potent dual inhibitor targeting c-Met and histone deacetylases (HDACs), exhibiting IC50 values of 18.49 nM for HDAC1 and 5.40 nM for c-Met. This compound demonstrates significant antiproliferative effects against various cancer cell lines, notably inducing G2/M-phase cell cycle arrest and apoptosis in HCT-116 cells. c-Met/HDAC-IN-2 is a valuable tool for investigating mechanisms of anti-cancer resistance and exploring therapeutic strategies in oncology research. -
HDAC inhibitor
HDAC-IN-67 is a potent inhibitor of histone deacetylases HDAC1 and HDAC6, demonstrating IC50 values of 22 nM and 8 nM, respectively. This compound effectively inhibits cell proliferation and induces apoptosis in various cancer cell lines. Its significant antitumor activity makes HDAC-IN-67 a valuable tool for cancer research and a potential candidate for therapeutic development. -
PIM-1/HDAC Inhibitor
PIM-1/HDAC-IN-1 is a selective inhibitor of PIM-1 as well as histone deacetylases HDAC 1 and HDAC 6, exhibiting an IC50 of 343.87 nM for PIM-1 and 63.65 nM and 62.39 nM for HDAC 1 and HDAC 6, respectively. This compound demonstrates significant apoptotic activity in MCF-7 cell lines, inducing pre-G1 apoptosis and causing cell cycle arrest at the G2/M phase. PIM-1/HDAC-IN-1 is a valuable tool for research on cancer biology and the regulation of cell proliferation and apoptosis. -
FGFR/HDAC Inhibitor
HDAC-IN-50 is a potent dual inhibitor targeting FGFR and HDAC with IC50 values of 0.18 nM for FGFR1, 1.2 nM for FGFR2, 0.46 nM for FGFR3, 1.4 nM for FGFR4, and varying inhibitory effects on HDAC isoforms such as HDAC1 (1.3 nM), HDAC2 (1.6 nM), HDAC6 (2.6 nM), and HDAC8 (13 nM). This compound effectively induces apoptosis and causes cell cycle arrest at the G0/G1 phase. Additionally, HDAC-IN-50 decreases the expression of phosphorylated forms of FGFR1, ERK, and STAT3, indicating its potential applications in cancer research and therapy. -
Tubulin/HDAC Inhibitor
Tubulin/HDAC-IN-1 is a dual inhibitor targeting tubulin and histone deacetylase 8 (HDAC8) through CH/π interaction and hydrogen bonding, respectively. This compound effectively inhibits tubulin polymerization and selectively inhibits HDAC8 with an IC50 value of 150 nM. Tubulin/HDAC-IN-1 demonstrates cytotoxic effects against a range of human cancer cell lines, induces cell cycle arrest in the G2/M phase, and promotes apoptosis. It is a valuable reagent for research involving hematologic malignancies and solid tumors, including neuroblastoma and leukemia. -
HDAC6 Inhibitor
SAHA-OH is a selective inhibitor of histone deacetylase 6 (HDAC6) with an IC50 of 23 nM, demonstrating a 10- to 47-fold selectivity over HDAC isoforms 1, 2, 3, and 8. This compound exhibits notable anti-inflammatory properties and has been shown to reduce macrophage apoptosis. It is a valuable tool for research focused on the modulation of histone acetylation and the investigation of HDAC6's role in various inflammatory pathways. -
VEGFR-2/HDAC Dual Inhibitor
VEGFR2/HDAC1-IN-1 is a potent dual inhibitor of VEGFR-2 and HDAC, demonstrating IC50 values of 57.83 nM and 9.82 nM, respectively. This compound effectively arrests the cell cycle at the S and G2 phases, leading to apoptosis in HeLa cells. Additionally, VEGFR2/HDAC1-IN-1 exhibits significant anti-angiogenic properties, making it a valuable tool for research in cancer biology and targeted therapies. -
HDAC Inhibitor
HDAC-IN-34 is a potent inhibitor of histone deacetylases (HDACs), demonstrating IC50 values of 0.022 μM for HDAC1 and 0.45 μM for HDAC6. This compound binds to DNA, leading to DNA damage and inducing apoptosis through the p53 signaling pathway. Additionally, HDAC-IN-34 exhibits significant anti-proliferative effects against HCT-116 colorectal cancer cells, with an IC50 of 1.41 μM, making it a valuable tool for cancer research and epigenetic studies. -
Xanthonoid Compound
Tovophyllin A is a xanthonoid compound that primarily targets neuroprotection through the activation of the Akt/GSK3β signaling pathway. This compound demonstrates significant neuroprotective effects against Parkinson's disease and induces Nrf2 activation to safeguard against liver injury in mouse models. Additionally, Tovophyllin A exhibits anti-inflammatory properties by inhibiting NF-κB activation and the subsequent release of pro-inflammatory cytokines, while also reducing apoptotic cell death. Its antiplasmodial and cytotoxic activities against lung epithelial and breast cancer cells further establish Tovophyllin A as a valuable reagent for research in diverse applications, including neurodegenerative diseases, liver injury, acute respiratory conditions, and cancer. -
NF-κB Inhibitor
NF-κB-IN-5 is a potent inhibitor of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) that acts by directly interacting with the NF-κB complex. This compound demonstrates significant antitumor activity across multiple human cancer cell lines, including HCT116, U87-MG, HepG2, BGC823, and PC9, with IC50 values ranging from 2.02 to 5.35 μM. NF-κB-IN-5 also promotes apoptosis in U87-MG cells and induces cell cycle arrest in the G0/G1 phase, positioning it as a valuable tool for cancer research and therapeutic development. -
Antitumor
CLEFMA is a curcuminoid known for its antitumor properties. It exhibits significant inhibition of tumor growth, primarily through the modulation of NF-κB pathways, leading to anti-inflammatory and anti-metastatic effects. This compound is utilized in research related to cancer biology and therapeutic development. -
HDAC/PSMD14 Inhibitor
HDAC/PSMD14-IN-1 is a dual-target inhibitor of HDAC1 and PSMD14, exhibiting IC50 values of 238.7 nM and 141.2 nM, respectively. This compound demonstrates significant cytotoxicity against esophageal squamous cell carcinoma (ESCC) cell lines, with IC50 values ranging from 30 to 250 nM. In addition to its ability to induce apoptosis, HDAC/PSMD14-IN-1 effectively reverses epithelial-mesenchymal transition (EMT) and shows promising anti-tumor activity in KYSE30 mouse xenograft models. It is a valuable tool for advancing research in esophageal cancer. -
HDAC Inhibitor
1-Alaninechlamydocin is a cyclic tetrapeptide that functions as a potent histone deacetylase (HDAC) inhibitor with an IC50 of 6.4 nM. This compound effectively induces G2/M cell cycle arrest and promotes apoptosis in MIA PaCa-2 cells, making it a valuable tool for cancer research. Its activity in modulating epigenetic regulation highlights its potential applications in therapeutic development and studies of cellular differentiation and survival. -
HDAC Class I Inhibitor
HDAC-IN-27 is a selective inhibitor of Class I histone deacetylases (HDAC1-3) with an IC50 range of 0.43 to 3.01 nM. It demonstrates significant anti-proliferative and pro-apoptotic effects against acute myeloid leukemia (AML) cell lines by promoting histone acetylation, specifically AcHH3 and AcHH4. This compound is valuable for research into the mechanisms of AML and potential therapeutic applications in histone modification regulation. -
HDAC6 Inhibitor
Daphnegiravone D is an inhibitor of HDAC6, targeting histone deacetylation to modulate gene expression. This compound demonstrates significant anti-hepatocellular carcinoma activity by inducing apoptosis and selectively inhibiting the proliferation of liver cancer cells. Its mechanism involves the p38 and JNK MAPK signaling pathways, making it a valuable tool for research in cancer therapeutics and cellular signaling. -
Apoptosi
NF023 is a selective inhibitor of X-BIR1/TAB1 assembly, impacting apoptosis by disrupting XIAP-mediated NF-κB activation. This compound modulates cell survival signaling pathways and demonstrates potential as a P2X1 adenylate receptor antagonist. NF023 may enhance the efficacy of pro-apoptotic therapies, offering a promising avenue for cancer treatment and suppression. -
HDAC1/6 Inhibitor
HDAC1/6-IN-1 is a potent inhibitor targeting HDAC1 and HDAC6, exhibiting IC50 values of 1.3 nM and 13 nM, respectively. This compound effectively inhibits the methylation and deacetylation of H3K9, leading to significant biological activity, including the induction of apoptosis in cancer cells, G0/G1 cell cycle arrest, and the inhibition of cell migration and invasion. It serves as a valuable tool in cancer research and the study of epigenetic regulation. -
c-Myc Inhibitor
EP12 is a selective c-Myc inhibitor that stabilizes c-Myc G-quadruplexes. This compound induces apoptosis and causes DNA damage in multiple myeloma cells, effectively inhibiting their growth. Additionally, EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway, highlighting its potential in cancer research and therapeutic applications. -
Neuroprotective Agent
Tricin 7-O-β-D-glucopyranoside functions as a potent neuroprotective agent, exhibiting significant oral bioavailability. This compound induces apoptosis and effectively reduces the expression levels of TNF-α mediated phospho-IκB-α, phospho-NF-κB, and HMGB1. Its activities make it a valuable reagent for research into neurodegenerative diseases and related biological pathways. -
Antioxidant Agent
Antioxidant agent-5 is a potent antioxidant that targets oxidative stress pathways. It effectively inhibits oxidized low-density lipoprotein (oxLDL)-induced apoptosis and the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in vascular endothelial cells. This compound suppresses oxLDL-mediated reactive oxygen species (ROS) production and nuclear translocation of NF-κB, providing protective effects against oxLDL-induced endothelial injury through the activation of the Nrf2/HO-1 antioxidant pathway. Research applications include studies on cardiovascular health and endothelial function. -
IRAK4 Inhibitor
Emavusertib phosphate is a potent inhibitor of IRAK4, exhibiting an IC50 of 57 nM. This compound effectively disrupts NF-κB and MyD88 signaling pathways, leading to a significant reduction in pro-inflammatory cytokines such as IL-6 and IL-10. Emavusertib phosphate demonstrates both anti-inflammatory and anti-proliferative effects on cancer cells, promoting apoptosis and showcasing antitumor activity in preclinical mouse models. Its applications extend to investigating inflammatory diseases and cancer therapies. -
Stable Isotope
N-Oxide Lidocaine-d10 is a deuterium-labeled derivative of Lidocaine, which primarily targets voltage-gated sodium channels, inhibiting their activity in a complex, use-dependent manner. This compound exhibits significant biological activity, notably reducing the growth, migration, and invasion of gastric carcinoma cells by up-regulating miR-145 expression and subsequently inactivating the MEK/ERK and NF-κB signaling pathways. N-Oxide Lidocaine-d10 is valuable for research into ventricular arrhythmias and related cardiac applications. -
IRAK4 Inhibitor
Emavusertib maleate is a potent inhibitor of IRAK4, demonstrating an IC50 of 57 nM, and FLT3. This orally bioavailable compound inhibits NF-κB and MyD88 signaling pathways, effectively reducing the production of pro-inflammatory cytokines such as IL-6 and IL-10. Its anti-inflammatory and anti-proliferative properties make it a valuable tool for cancer research, promoting apoptosis in cancer cells and demonstrating antitumor activity in preclinical mouse models. -
Stable Isotope
Sodium propionate-13C-1 is a stable isotope-labeled derivative of sodium propionate, functioning primarily as a short-chain fatty acid. It is synthesized by intestinal bacteria through dietary fiber metabolism and exhibits multiple biological activities, including increased PPAR-γ expression and inhibition of NF-κB activation, COX-2 expression, and NO production. Additionally, sodium propionate induces apoptosis and autophagy while demonstrating neuroprotective, antioxidant, and anti-inflammatory properties. Its applications span various research areas, including spinal cord injury, Alzheimer's disease, and glioblastoma, presenting potential avenues for therapeutic exploration. -
NF-κB Inhibitor
Amorfrutin A is an NF-κB inhibitor that inhibits TNF-α-induced IκBα degradation, p65 nuclear translocation, and DNA-binding activity of the NF-κB complex. This compound promotes apoptosis in HeLa cells by enhancing the proteolytic activities of caspase-3 and PARP. Its mechanism suggests potential research applications in studying inflammation, cancer biology, and cell death pathways. -
IRAK4 Inhibitor
Emavusertib tosylate is a potent inhibitor of IRAK4, displaying an IC50 of 57 nM. By targeting IRAK4 and FLT3, it effectively disrupts NF-κB and MyD88 signaling pathways, resulting in the reduction of pro-inflammatory cytokines such as IL-6 and IL-10. This compound demonstrates significant anti-inflammatory and anti-proliferative properties against cancer cells, promoting apoptotic mechanisms. Additionally, Emavusertib tosylate has shown noteworthy antitumor activity in preclinical mouse models, making it a valuable reagent for cancer research and inflammation studies. -
TAK1 Inhibitor
Triptriolide is a TAK1 inhibitor that plays a pivotal role in regulating apoptosis in mouse podocytes. It enhances cell survival and protects podocyte function by modulating the Bcl-2 family proteins and inhibiting Caspase-3 activity. Additionally, Triptriolide activates the TAK1-NF-κB signaling pathway, leading to the upregulation of podocin. This reagent is relevant for studies focusing on kidney health and podocyte resilience under stress conditions. -
Stable Isotope
Lidocaine-d6 is a deuterated form of Lidocaine, serving as a stable isotope for metabolic studies and analytical applications. Lidocaine primarily targets sodium channels, exhibiting voltage-dependent inhibition. In cancer research, it has been shown to reduce growth, migration, and invasion of gastric carcinoma cells by up-regulating miR-145, which leads to the inactivation of the MEK/ERK and NF-κB signaling pathways. This compound is also relevant for studies on ventricular arrhythmias, providing insights into cardiac electrophysiology. -
Stable Isotope
Carbocisteine-13C3-1 is a stable isotope-labeled derivative of Carbocisteine, primarily targeting mucolytic activity. This compound is known to inhibit the phosphorylation of NF-κB p65 and ERK1/2, modulating the interplay between Nrf2 and HO-1. Additionally, Carbocisteine exhibits apoptotic inhibition properties. It is widely employed in research related to chronic obstructive pulmonary disease (COPD) and other respiratory conditions. -
Antimalarial
Quinacrine methanesulfonate is a potent orally active antimalarial compound that also exhibits antitumor properties. This reagent functions through the inhibition of NF-κB signaling and the activation of p53 pathways, leading to apoptosis in cancer cells. Its dual activity makes it valuable for studying both malaria pathogenesis and cancer biology. -
Stable Isotope
Propanoic acid-13C3 is a stable isotope-labeled derivative of propanoic acid, targeting metabolic pathways involving short-chain fatty acids. This compound demonstrates significant biological activity by enhancing PPAR-γ expression, inhibiting NF-κB activation, and downregulating COX-2 and nitric oxide production. Additionally, propanoic acid-13C3 has been shown to induce apoptosis and autophagy, display neuroprotective effects, and exhibit anti-inflammatory properties. Its applications extend to research in spinal cord injury, Alzheimer's disease, and glioblastoma therapy, making it a valuable tool for metabolic and neurological studies. -
IRAK4 Inhibitor
Emavusertib mesylate is a potent inhibitor of IRAK4, demonstrating an IC50 of 57 nM. This orally active compound effectively disrupts the NF-κB and MyD88 signaling pathways, leading to a reduction in pro-inflammatory cytokines such as IL-6 and IL-10. Emavusertib mesylate displays anti-inflammatory and anti-proliferative properties against cancer cells, promoting apoptosis. Additionally, it has shown significant antitumor activity in mouse models, making it valuable for cancer research and therapeutic studies targeting inflammatory pathways. -
BChE Inhibitor
Pteryxin is a potent butyrylcholinesterase (BChE) inhibitor (IC50 = 12.96 μg/mL) with additional multi-target mechanisms including inhibition of NF-κB, MAPK, NLRP3 inflammasome activation, and modulation of the Nrf2/ARE pathways. This compound demonstrates significant anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin is suitable for research applications related to inflammatory diseases, osteoporosis, diabetes, and neurodegenerative disorders such as Alzheimer's disease. -
PC Inhibitor
Anemoside A3-methyl 6-aminohexanoate is a potent pyruvate carboxylase (PC) inhibitor, exhibiting a Kd value of 10.1 μM against human PC. This compound influences cellular pathways through the PC/NF-κB/NLRP3 inflammasome axis, demonstrating significant efficacy in alleviating symptoms of DSS-induced colitis in murine models. Anemoside A3-methyl 6-aminohexanoate serves as a useful tool in colitis-related research and studies focusing on the modulation of inflammatory pathways. -
NLRP3 Inhibitor
Yadanzigan is a potent NLRP3 inhibitor that exerts its anti-inflammatory effects by inhibiting the NF-κB signaling pathway and reducing Reactive Oxygen Species production. This compound has been shown to mitigate LPS-induced acute lung injury (ALI) in murine models, highlighting its potential for research in inflammation-related conditions. Its mechanism of action positions Yadanzigan as a valuable tool for studying NLRP3-related pathways and their roles in various pathological processes. -
NOD1 Agonist
iE-DAP is a potent NOD1 agonist that activates the NOD1 receptor, leading to the stimulation of the NF-κB and MLCK signaling pathways. This results in enhanced cellular inflammatory responses and disruption of tight junction integrity, as evidenced by the downregulation of ZO-1 and Occludin gene expression. In term human trophoblast cell cultures, iE-DAP promotes the secretion of pro-inflammatory cytokines such as IL-6, GRO-α, MCP-1, IL-8, and MIP-1β. It is particularly relevant for research focused on mastitis and preterm birth, as it has been shown to induce fetal inflammation and impact fetal body weight in pregnant murine models. -
Sodium Channel Inhibitor
Articaine is a selective inhibitor of voltage-gated sodium channels, including rNav1.4, hNav1.7, and rNav1.8, demonstrating an IC50 of 15.8 μM for open-state Na+ channels. It effectively blocks Na+ influx, leading to local anesthetic effects and interruption of nerve impulse conduction. Additionally, Articaine exhibits anti-inflammatory properties by inhibiting NF-κB activation and the NLRP3 inflammasome pathway. This compound is valuable for research in dental anesthesia and inflammatory-related conditions, such as acute kidney injury. -
NLRP3 Inhibitor
NLRP3-IN-69 is a selective inhibitor of the NLRP3 inflammasome, targeting the activation of NF-κB p65. This compound effectively reduces LPS-induced overexpression of pro-inflammatory cytokines including IL-1β, as well as iNOS and COX-2, while inhibiting nitric oxide generation with an IC50 of 5.66 μM. NLRP3-IN-69 serves as a valuable tool in research focused on inflammatory diseases and the modulation of the immune response. -
COX-2/NLRP3 Inhibitor
COX-2/NLRP3-IN-1 is a selective inhibitor targeting both COX-2 and the NLRP3 inflammasome, with an IC50 of 1.53 μM for COX-2. This compound exhibits notable anti-inflammatory properties by disrupting the NF-κB/NLRP3 signaling pathway, making it a valuable tool for research into inflammatory diseases. It is suitable for studying the roles of COX-2 and NLRP3 in various biological processes and therapeutic interventions. -
NOD1/NOD2 Antagonist
NOD1/2 antagonist-2 is a dual antagonist of NOD1 and NOD2, exhibiting IC50 values of 2.36 μM and 4.16 μM, respectively. This compound effectively inhibits NF-κB and MAPK inflammatory signaling pathways, enhancing the efficacy of Paclitaxel in suppressing the growth of Lewis lung carcinoma. It is a valuable tool for investigating the roles of NOD1 and NOD2 in inflammation and cancer research. -
NF-κB Inhibitor
1-Caffeoylquinic acid is a potent inhibitor of NF-κB, demonstrating a significant binding affinity to the RH domain of p105 with a Ki value of 0.007 μM. This compound exhibits notable anti-oxidative stress properties and serves as an inhibitor for the PD-1/PD-L1 pathway. Its biological activities make it valuable for research applications in inflammation, immunity, and cancer studies. -
T-cell Activator
Phytohemagglutinin (PHA-M) is a potent T-cell activator derived from the seeds of Phaseolus vulgaris. This lectin stimulates the proliferation of human mononuclear leukocytes, leading to the upregulation of ChAT mRNA and enhancing acetylcholine synthesis. Additionally, Phytohemagglutinin exerts dose- and time-dependent cytotoxic effects on THP-1 monocytes/macrophages, resulting in altered cellular morphology, organelle dysfunction, and increased expression of pro-inflammatory markers such as NF-κB, COX2, and IL-1β. It is valuable for research applications related to immunology and cell signaling pathways. -
Natural Product
Sesame Oil is a natural product derived from the seeds of Sesamum indicum L. It exhibits a variety of biological activities, including the ability to reduce NF-κB, aspartate aminotransferase, alanine aminotransferase, IL-1β, IL-4, and nitric oxide levels. Sesame Oil demonstrates antitumor activity against malignant melanoma and provides protective effects against liver damage induced by agents such as Cisplatin and Acetaminophen. Additionally, it possesses notable antinociceptive and anti-inflammatory properties, making it a valuable reagent for various research applications.
